光晟生技 (7561.TW) 2025Q4 financial report shows revenue of 108.59M TWD, with a YoY growth rate of -6.32%. Although revenue has slightly decreased compared to the same period last year, reflecting changes in industry demand, the company’s operations remain relatively stable. To fully assess 光晟生技 (7561.TW)’s potential risks and future development, investors should continue to monitor subsequent financial reports and strategic adjustments, and use diversified data analysis, including Growin AI Value Analysis, for a prudent and comprehensive evaluation.